Is this you? Create Your Porfile
Avatar

Rafal Swiercz

University of Toledo Medical Center

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Rafal Swiercz is active.

Explore More

Publication

Featured researches published by Rafal Swiercz.

Nature | 1997

Why drinking green tea could prevent cancer

Jerzy Jankun; Steven H. Selman; Rafal Swiercz; Ewa Skrzypczak-Jankun

Epidemiological studies suggest that the consumption of green tea may help prevent cancers in humans; also, breast and prostate cancers in animal models are reduced by green, but not black, tea. Here we offer a possible explanation. We have inferred (using molecular modelling) and subsequently demonstrated that one of the major ingredients of green tea inhibits urokinase, an enzyme crucial for cancer growth.

Cancer Research | 1997

Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice

Jerzy Jankun; Rick W. Keck; Ewa Skrzypczak-Jankun; Rafal Swiercz

Oncology Reports | 1999

Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.

Rafal Swiercz; Ewa Skrzypczak-Jankun; Matt M. Merrell; Steven H. Selman; Jerzy Jankun

Molecular Cancer Therapeutics | 2003

A Novel Form of the Plasminogen Activator Inhibitor Created by Cysteine Mutations Extends Its Half-Life: Relevance to Cancer and Angiogenesis1

Joanna Chorostowska-Wynimko; Rafal Swiercz; Ewa Skrzypczak-Jankun; Adam Wójtowicz; Steven H. Selman; Jerzy Jankun

Oncology Reports | 2001

Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice

Rafal Swiercz; Rick W. Keck; Ewa Skrzypczak-Jankun; Steven H. Selman; Jerzy Jankun

Clinical Cancer Research | 1998

Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.

Rafal Swiercz; Jeremy D. Wolfe; Aiman Zaher; Jerzy Jankun

Oncology Reports | 2004

Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells

Joanna Chorostowska-Wynimko; Rafal Swiercz; Ewa Skrzypczak-Jankun; Steven H. Selman; Jerzy Jankun

Archive | 2003

Modified plasminogen inhibitor type-1 and methods based thereon

Rafal Swiercz; Steven H. Selman; Jerzy Jankun; Ewa Skrzypczak-Jankun; Joanna Chorostowska-Wynimko

Archive | 2003

Modified plasminogen activator inhibitor type-1 and methods based thereon

Rafal Swiercz; Steven H. Selman; Jerzy Jankun; Joanna Chorostowska-Wynimko; Ewa Skrzypczak-Jankun

Archive | 2003

Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren Modified type-1 plasminogen activator inhibitor and based thereon procedure

Rafal Swiercz; Steven H. Selman; Jerzy Jankun; Ewa Skrzypczak-Jankun; Joanna Chorostowska-Wynimko

Explore More

Collaboration

Dive into the Rafal Swiercz's collaboration.

Top Co-Authors
Avatar

Jerzy Jankun

University of Toledo Medical Center

View shared research outputs
Top Co-Authors
Avatar

Ewa Skrzypczak-Jankun

University of Toledo

View shared research outputs
Top Co-Authors
Avatar

Steven H. Selman

Ohio University

View shared research outputs
Top Co-Authors
Avatar

Joanna Chorostowska-Wynimko

Medical University of Warsaw

View shared research outputs
Top Co-Authors
Avatar

Joanna Chorostowska-Wynimko

Medical University of Warsaw

View shared research outputs
Top Co-Authors
Avatar

Rick W. Keck

University of Toledo Medical Center

View shared research outputs
Top Co-Authors
Avatar

Matt M. Merrell

University of Toledo Medical Center

View shared research outputs
Top Co-Authors
Avatar

Adam Wójtowicz

Poznań University of Economics

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge